HEALTH

BRUSSELS — GlaxoSmithKline has garnered strong interest in its portfolio of legacy brands that were placed on the sales block earlier this year, according to a Reuters report published Tuesday. And that interest is likely to pick up in the coming months, GSK CEO Andrew Witty told reporters during a meeting of pharmaceutical industry executives.

The interest is coming from both established consumer healthcare companies, as well as private equity houses, the report noted.

ROCKVILLE, Md. — The Food and Drug Administration on Monday announced that a consent decree of condemnation, forfeiture and permanent injunction has been filed against H&P Industries, Triad Group and three individuals, which would prevent them from manufacturing and distributing products from their Hartland, Wis., facility, or any other location.

BOSTON — Men with prostate cancer are at a higher risk of developing diabetes or diabetes risk factors if they receive a therapy designed to block the production of testosterone, a new study has suggested.

IRVINE, Calif. — ChromaDex on Monday announced it will launch a supplement line in GNC called BluScience in July.

"We are extremely excited about the BluScience launch with GNC, given the innovative and novel ingredient pTeroPure, which is the foundation for the BluScience line," GNC VP merchandising Ted Deitrick said.

SILVER SPRING, Md. — The Food and Drug Administration has approved changes to the labels of several drugs made by Merck, the agency said Friday.

Merck’s Label Standardization Project includes the revision of 34 container labels for 16 drugs, all orally administered pills. These include the cardiovascular drugs Cozaar (losartan) and Hyzaar (losartan and hydrochlorothiazide), the diabetes drugs Januvia (sitagliptin) and Janumet (sitagliptin and metformin), the allergy and asthma drug Singulair (montelukast), the HIV drug Isentress (raltegravir) and others.

NEW YORK and WATERTOWN, Mass. — The Juvenile Diabetes Research Foundation and Selecta Biosciences have established a research collaboration to develop vaccines for Type 1 diabetes, also known as juvenile diabetes.

Through the collaboration, JDRF will provide "milestone-based financial support and expertise" to Selecta, which ultimately would apply its vaccine technology to create a vaccine that would halt or prevent the autoimmune response that causes Type 1 diabetes.

MT. KISCO, N.Y. — Increasingly, social media is leveling the playing field for small- and mid-sized brand marketers, opening new, more affordable and more effective avenues to communicate with consumers versus such traditional media as TV and radio. And new research suggests the balance of power already may be tipping in favor of social marketing, particularly in certain categories and definitely among certain consumers.

INDIANAPOLIS — A federal court has ruled in favor of drug maker Eli Lilly in a dispute with Amylin Pharmaceuticals over Lilly’s partnership with German drug maker Boehringer Ingelheim.